Samir Rashmikant Patel insider trades

Open-market stock purchases and sales by Samir Rashmikant Patel, Director at Akari Therapeutics plc, from SEC Form 4 filings since Apr 17, 2020.

Recent trades

DateStockTradeValue
Oct 5, 2026AKTX Akari Therapeutics plcBought (not open market)$17.7K
Aug 18, 2026AKTX Akari Therapeutics plcBought (not open market)$49.8K
Aug 18, 2026AKTX Akari Therapeutics plcBought (not open market)—
Aug 18, 2026AKTX Akari Therapeutics plcBought (not open market)—
Jul 7, 2026AKTX Akari Therapeutics plcBought (not open market)$9.7K
Jul 7, 2026AKTX Akari Therapeutics plcBought (not open market)$6
Jul 7, 2026AKTX Akari Therapeutics plcBought (not open market)$2
Jul 7, 2026AKTX Akari Therapeutics plcBought (not open market)$38.7K
Jul 7, 2026AKTX Akari Therapeutics plcBought (not open market)$250K
Jul 7, 2026AKTX Akari Therapeutics plcBought (not open market)$93.7K
Dec 16, 2025AKTX Akari Therapeutics plcBought$250K
Dec 16, 2025AKTX Akari Therapeutics plcBought$93.7K

Companies traded

  • AKTX Akari Therapeutics plc: 2 buys, last Oct 5, 2026
  • CYDY CytoDyn Inc: other filings, last Nov 24, 2021

Get free alerts when Samir Rashmikant Patel files a new trade →